PID1 Activators
Chemical activators of phosphotyrosine interaction domain containing 1 play a distinct role in the modulation of its activity through various biochemical pathways. Piceatannol and Genistein, for instance, influence phosphotyrosine interaction domain containing 1 by intervening at different points of the kinase signaling cascade. Piceatannol acts by inhibiting Syk kinase, a pivotal enzyme upstream of phosphotyrosine interaction domain containing 1, thus potentially leading to a circumvention of the usual negative regulatory mechanisms and subsequent activation of the protein. Genistein, on the other hand, indirectly heightens tyrosine phosphorylation by inhibiting tyrosine phosphatases, thereby increasing the availability of phosphorylated substrates for phosphotyrosine interaction domain containing 1 and facilitating its activation.
Furthermore, Src family kinases, which are critical mediators in cellular signaling, are targeted by compounds like PP2, SU6656, and PP1. These inhibitors can inadvertently prompt the activation of alternative pathways that converge on phosphotyrosine interaction domain containing 1. Herbimycin A and Lavendustin A, both tyrosine kinase inhibitors, can also lead to increased phosphorylation of proteins, thereby activating signaling pathways that involve phosphotyrosine interaction domain containing 1. Daidzein, similar to Genistein, modulates the kinase network to increase phosphotyrosine signaling, which in turn can activate phosphotyrosine interaction domain containing 1. AG490, by targeting JAK2 kinase, can result in the activation of other signaling cascades that involve phosphotyrosine interaction domain containing 1. Tyrphostin AG 528 and Tyrphostin AG 879, by inhibiting tyrosine kinases and Trk receptors respectively, allow for the possibility of compensatory pathway activation that can lead to phosphotyrosine interaction domain containing 1 activity. Finally, PD 168393, which irreversibly inhibits EGFR tyrosine kinase, can facilitate the activation of alternative signaling routes that may involve phosphotyrosine interaction domain containing 1, highlighting the intricate network of signaling pathways and the potential for cross-talk between different signaling molecules in the regulation of this protein's activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Piceatannol | 10083-24-6 | sc-200610 sc-200610A sc-200610B | 1 mg 5 mg 25 mg | $51.00 $71.00 $199.00 | 11 | |
Piceatannol has been shown to inhibit the activity of Syk kinase, which is upstream of phosphotyrosine interaction domain containing 1 activation. By inhibiting negative regulators, piceatannol can lead to the activation of downstream proteins including phosphotyrosine interaction domain containing 1. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein is a tyrosine kinase inhibitor that can specifically increase tyrosine phosphorylation levels indirectly by inhibiting tyrosine phosphatases. Elevated tyrosine phosphorylation can enhance the activity of phosphotyrosine interaction domain containing 1 by increasing its substrate availability. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an Src family kinase inhibitor. Inhibition of Src family kinases can lead to compensatory activation of alternative pathways that signal through proteins like phosphotyrosine interaction domain containing 1, thereby promoting its activation. | ||||||
Herbimycin A | 70563-58-5 | sc-3516 sc-3516A | 100 µg 1 mg | $277.00 $1532.00 | 13 | |
Herbimycin A is a tyrosine kinase inhibitor that can lead to increased phosphorylation of proteins by inhibiting phosphatase activity indirectly. This can result in the activation of signaling pathways involving phosphotyrosine interaction domain containing 1. | ||||||
Daidzein | 486-66-8 | sc-24001 sc-24001A sc-24001B | 100 mg 500 mg 5 g | $28.00 $79.00 $165.00 | 32 | |
Daidzein, like genistein, inhibits tyrosine kinases indirectly leading to increased phosphotyrosine signaling, which can activate downstream targets including phosphotyrosine interaction domain containing 1. | ||||||
SU6656 | 330161-87-0 | sc-203286 sc-203286A | 1 mg 5 mg | $57.00 $133.00 | 27 | |
SU6656 is a selective Src family kinase inhibitor. By selectively inhibiting certain kinases, it can lead to activation of compensatory signaling pathways that involve phosphotyrosine interaction domain containing 1 activation. | ||||||
AG-490 | 133550-30-8 | sc-202046C sc-202046A sc-202046B sc-202046 | 5 mg 50 mg 25 mg 10 mg | $84.00 $329.00 $223.00 $87.00 | 35 | |
AG490 is a tyrosine kinase inhibitor, particularly of JAK2. Inhibition of JAK2 can lead to the activation of alternative signaling pathways that can include the activation of phosphotyrosine interaction domain containing 1. | ||||||
Tyrphostin AG 879 | 148741-30-4 | sc-3557 sc-3557A | 5 mg 25 mg | $83.00 $328.00 | 4 | |
Tyrphostin AG 879 inhibits Trk receptors, which may lead to the compensatory activation of phosphotyrosine signaling pathways involving phosphotyrosine interaction domain containing 1. | ||||||
Lavendustin A | 125697-92-9 | sc-200539 sc-200539A | 1 mg 5 mg | $116.00 $456.00 | ||
Lavendustin A inhibits tyrosine kinases and can lead to the activation of alternative pathways that promote the activation of phosphotyrosine interaction domain containing 1. | ||||||
Imatinib mesylate | 220127-57-1 | sc-202180 sc-202180A | 25 mg 100 mg | $45.00 $111.00 | 61 | |
PD 168393 is an irreversible inhibitor of EGFR tyrosine kinase. Inhibition of EGFR can result in the activation of alternative signaling pathways, potentially leading to the activation of phosphotyrosine interaction domain containing 1. | ||||||